Voyageur Pharmaceuticals Ltd. (VYYRF)
Voyageur Pharmaceuticals Ltd. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Calgary, AB, CA. The stock last traded at $0.12, up 4.35% on the session, giving a market capitalisation of $21.5M. On trailing twelve-month figures it carries a trailing P/E of -7.60, a net margin of -8033.9%. Its beta of 0.29 implies it has historically moved less than the broad market.
Voyageur Pharmaceuticals Ltd. is dedicated to extracting active pharmaceutical ingredients (APIs) from various mineral resources. The firm's strategic objectives include manufacturing radiocontrast compounds derived from barium and iodine, in addition to developing pharmaceuticals that incorporate bromine. The company boasts complete ownership of three barium sulfate deposits in British Columbia, Canada, with two sites offering material suitable for the pharmaceutical barite industry. Furthermore, Voyageur holds stakes in a rich brine project in Utah, USA, which contains high concentrations of iodine, lithium, and bromine. The entity, which was previously named Voyageur Minerals Ltd., adopted its current moniker, Voyageur Pharmaceuticals Ltd., in December 2019. Headquartered in Calgary, Canada, the company operates from this location.
Voyageur Pharmaceuticals Ltd. is most often compared with the following Healthcare names: